Recursion Pharmaceuticals vs GE HealthCare

Side-by-side comparison of AI visibility scores, market position, and capabilities

GE HealthCare leads in AI visibility (93 vs 48)
Recursion Pharmaceuticals logo

Recursion Pharmaceuticals

ChallengerHealthcare Tech

AI Drug Discovery / Computational Biology

Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City.

AI VisibilityBeta
Overall Score
C48
Category Rank
#1 of 1
AI Consensus
49%
Trend
up
Per Platform
ChatGPT
39
Perplexity
58
Gemini
47

About

Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.

Full profile
GE HealthCare logo

GE HealthCare

LeaderHealthcare Tech

Enterprise

Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.

AI VisibilityBeta
Overall Score
A93
Category Rank
#183 of 290
AI Consensus
61%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
95
Gemini
85

About

GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.

Full profile

AI Visibility Head-to-Head

48
Overall Score
93
#1
Category Rank
#183
49
AI Consensus
61
up
Trend
stable
39
ChatGPT
99
58
Perplexity
95
47
Gemini
85
39
Claude
84
53
Grok
89

Key Details

Category
AI Drug Discovery / Computational Biology
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Recursion Pharmaceuticals
AI Drug Discovery / Computational Biology

Integrations

Only Recursion Pharmaceuticals
Recursion Pharmaceuticals is classified as company. GE HealthCare is classified as company (part of GE Aerospace).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.